Patrick Lavery

1 day ago | biopharminternational.com | Patrick Lavery

The France-based genetic medicines developer EG 427 has provided details on its two posters exhibited on the first night of the 28th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), running from May 13–17, 2025 in New Orleans (1). Vector technology proven effectiveData presented by the company in the posters focused on the HSV-1 genome and EG 427’s role in developing non-replicating HSV-1 (nrHSV-1) vector technology for neurology applications (1).

3 days ago | biopharminternational.com | Patrick Lavery

The biotechnology company Genentech, a member of the Roche Group, announced on May 12, 2025, that it will invest more than $700 million in a new, state-of-the-art drug manufacturing facility in Holly Springs, NC, Genentech’s first facility to be built on the East Coast of the United States (1). The Roche Group has several other East Coast properties outside the Genentech brand.

1 week ago | biopharminternational.com | Patrick Lavery

REGENXBIO, a Rockville, Md.-based clinical-stage biotechnology company, is announcing its slate of oral and poster presentations to be made at the American Society of Gene & Cell Therapy (ASGCT)’s 28th annual meeting, which will be held in New Orleans from May 13–17, 2025 (1).

1 week ago | biopharminternational.com | Patrick Lavery

So far in 2025, BioPharm International® has taken a look at outsourcing in terms of the steps in the processes of developing and producing biologics, analytical technologies that can best align with process monitoring and optimization, and how newly-formed partnerships are helping to ease capacity shortages (1–3). At the same time, innovation continues to push forward, with sustainability and cost savings near the top of the list of priorities (4,5).

1 week ago | biopharminternational.com | Patrick Lavery

United States President Donald Trump has signed an executive order containing several directives to FDA and the Environmental Protection Agency (EPA), aiming to reduce regulatory barriers and restore a robust domestic manufacturing base for prescription drugs (1).